Skip to main content

Table 2 Ocular Inflammatory Events Description

From: Ocular inflammatory events following COVID-19 vaccination: a multinational case series

 

Variable

Total

(%)

(N = 70)

Anterior Uveitis (%)

(N = 41)

Posterior Uveitis (%)

(N = 9)

Scleritis (%)

(N = 7)

Others (%)

(N = 13)

Previous Ocular Inflammatory Events

Number of patients

36 (51.4)

23 (56.1)

3 (33.3)

5 (71.4)

5 (38.5)

Controlled more than 3 months

28 (82.4)

17 (81.0)

3 (100)

3 (60.0)

5 (100)

On Topical Anti-inflammatory

1 (2.8)

1 (4.3)

0 (0.0)

0 (0.0)

0 (0.0)

On Systemic Anti-inflammatory

7 (19.4)

4 (17.4)

0 (0.0)

1 (20.0)

2 (15.4)

Event similar to previous events

34 (94.4)

23 (100.0)

2 (66.7)

5 (100.0)

4 (80)

Presentation

Unilateral

60 (85.7)

33 (80.5)

8 (88.9)

7 (100)

12 (92.3)

Bilateral

10 (14.3)

8 (19.5)

1 (11.1)

0 (0.0)

1 (7.7)

VA Unaffected

38 (54.3)

22 (53.7)

2 (22.2)

6 (85.7)

8 (61.5)

VA reduced ≤ 3 lines

18 (25.7)

10 (24.4)

4 (44.4)

1 (14.3)

3 (23.1)

VA reduced > 3 lines

14 (20.0)

9 (22.0)

3 (33.3)

0 (0.0)

2 (15.4)

Management

Topical Corticosteroids

48 (68.6)

34 (82.9)

3 (33.3)

6 (85.7)

5 (38.5)

Systemic Corticosteroids

13 (18.6)

2 (4.9)

6 (66.7)

1 (14.3)

4 (30.8)

Antivirals

6 (8.6)

5 (12.2)

0 (0.0)

0 (0.0)

1 (7.7)

NSAIDs

2 (2.9)

0 (0.0)

0 (0.0)

1 (14.3)

1 (7.7)

Antibiotics

4 (5.7)

0 (0.0)

4 (44.4)

0 (0.0)

0 (0.0)

Visual Outcomes

VA Unaffected

65 (92.9)

39 (95.1)

7 (77.8)

7 (100)

12 (92.3)

VA reduced ≤ 3 lines

2 (2.9)

1 (2.4)

0 (0.0)

0 (0.0)

1 (7.7)

VA reduced > 3 lines

3 (4.3)

1 (2.4)

2 (22.2)

0 (0.0)

0 (0.0)

Complications

Transient IOP elevation

3 (4.3)

3 (7.3)

0 (0.0)

0 (0.0)

0 (0.0)

Nummular Corneal Lesions

1 (1.4)

1 (2.4)

0 (0.0)

0 (0.0)

0 (0.0)

Cystoid Macular Oedema

2 (2.9)

1 (2.4)

0 (0.0)

0 (0.0)

1 (7.7)

Macular Scarring

2 (2.9)

0 (0.0)

2 (22.2)

0 (0.0)

0 (0.0)